Nuvectis Pharma, INC Form 4 insider transactions

A Nuvectis Pharma director, Charles Mosseri-Marlio, amended a previous filing to include a stock purchase made on December 12, 2024, and to correct the total amount of securities beneficially owned.

Director Charles Mosseri-Marlio of Nuvectis Pharma, Inc. purchased 17,000 shares of common stock at $4.7 per share.

Enrique Poradosu, Chief Science & Business Officer of Nuvectis Pharma, acquired 2,000 shares of common stock at an average price of $4.99.

Nuvectis Pharma's CEO, Ron Bentsur, purchased 20,000 shares of common stock at an average price of $4.92.

Michael J. Carson, Vice President of Finance at Nuvectis Pharma, Inc., reports acquisition and disposal of company stock, including vesting of restricted stock and sales to cover tax obligations.

Director Matthew L. Kaplan acquired 30,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Director Kenneth Hoberman of Nuvectis Pharma, Inc. receives 30,000 shares of restricted common stock.

Director James F. Oliviero III acquired 30,000 shares of restricted common stock in Nuvectis Pharma, Inc. on June 13, 2024.

Ron Bentsur, Chairman & CEO of Nuvectis Pharma, recently purchased 1,940 shares of common stock, increasing his total holdings to 3,246,424 shares.

Nuvectis Pharma's Chairman and CEO, Ron Bentsur, recently acquired 2,000 shares of common stock in the open market, increasing his total holdings.

Enrique Poradosu, Chief Science & Business Officer of Nuvectis Pharma, recently acquired 500 shares of common stock at $6.29 per share.

Shay Shemesh, Chief Development & Operations Officer of Nuvectis Pharma, recently purchased additional shares of the company's common stock in the open market.

Ron Bentsur, Chairman and CEO of Nuvectis Pharma, recently purchased 5,000 shares of the company's common stock at a price of $10.29 per share.